相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
The International Association for the Study of Lung Cancer Global Survey on Molecular Testing in Lung Cancer
Matthew P. Smeltzer et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Low-Dose Erlotinib Treatment in Elderly or Frail Patients With EGFR Mutation-Positive Non-Small Cell Lung Cancer A Multicenter Phase 2 Trial
Shingo Miyamoto et al.
JAMA ONCOLOGY (2020)
Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer A Review
Kathryn C. Arbour et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Safety outcomes in advanced non-small-cell lung cancer patients treated with first-line platinum-based regimens in the United States
Lei Chen et al.
JOURNAL OF THORACIC DISEASE (2019)
Osimertinib in Elderly Patients with Epidermal Growth Factor Receptor T790M-Positive Non-Small-Cell Lung Cancer Who Progressed During Prior Treatment: A Phase II Trial
Akira Nakao et al.
ONCOLOGIST (2019)
Genotyping KRAS and EGFR Mutations in Greek Patients With Non-small-cell Lung Cancer: Incidence, Significance and Implications for Treatment
Helena Linardou et al.
CANCER GENOMICS & PROTEOMICS (2019)
The clinical features of older patients with lung cancer in comparison with their younger counterparts
Hirokazu Ogino et al.
RESPIRATORY INVESTIGATION (2019)
Erlotinib treatment after platinum-based therapy in elderly patients with non-small-cell lung cancer in routine clinical practice - results from the ElderTac study
Wolfgang M. Brueckl et al.
BMC CANCER (2018)
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
D. Planchard et al.
ANNALS OF ONCOLOGY (2018)
A phase II study of afatinib treatment for elderly patients with previously untreated advanced non-small-cell lung cancer harboring EGFR mutations
Hisao Imai et al.
LUNG CANCER (2018)
Cost-effectiveness of precision medicine in the fourth-line treatment of metastatic lung adenocarcinoma: An early decision analytic model of multiplex targeted sequencing
Brett Doble et al.
LUNG CANCER (2017)
Lung Cancer in the Older Patient
Julie A. Barta et al.
CLINICS IN GERIATRIC MEDICINE (2017)
Global Cancer Incidence and Mortality Rates and Trends-An Update
Lindsey A. Torre et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2016)
Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)
Fabrice Barlesi et al.
LANCET (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Global Cancer Statistics, 2012
Lindsey A. Torre et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
Phase II study of erlotinib in elderly patients with non-small cell lung cancer harboring epidermal growth factor receptor mutations
Yusuke Inoue et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
Assessment of Mutational Profile of Japanese Lung Adenocarcinoma Patients by Multitarget Assays
Masakuni Serizawa et al.
CANCER (2014)
Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
Mark G. Kris et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial
Marina Chiara Garassino et al.
LANCET ONCOLOGY (2013)
First-Line Gefitinib in Patients Aged 75 or Older With Advanced Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations NEJ 003 Study
Makoto Maemondo et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study
Tudor Ciuleanu et al.
LANCET ONCOLOGY (2012)
Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial
Elisabeth Quoix et al.
LANCET (2011)
Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR.
Makoto Maemondo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
First-Line Gefitinib for Patients With Advanced Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Without Indication for Chemotherapy
Akira Inoue et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Erlotinib for advanced non-small-cell lung cancer in the elderly: An analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21
Paul Wheatley-Price et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Safety and efficacy of gefitinib treatment in elderly patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group experience
K Hotta et al.
ACTA ONCOLOGICA (2005)
Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC)
F Cappuzzo et al.
BRITISH JOURNAL OF CANCER (2004)
分享论文
